Get the Stockscreener App
61.09
0.21%
0.13
After Hours:
61.09
Ptc Therapeutics Inc stock is traded at $61.09, with a volume of 1.76M.
It is up +0.21% in the last 24 hours and up +34.95% over the past month.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
See More
Previous Close:
$60.96
Open:
$60.92
24h Volume:
1.76M
Relative Volume:
1.46
Market Cap:
$4.85B
Revenue:
$900.66M
Net Income/Loss:
$-453.20M
P/E Ratio:
-10.28
EPS:
-5.94
Net Cash Flow:
$-274.19M
1W Performance:
+6.69%
1M Performance:
+34.95%
6M Performance:
+13.95%
1Y Performance:
+86.82%
1-Day Range:
$60.48
$62.18
1-Week Range:
$56.51
$62.18
52-Week Range:
$33.19
$62.18
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
61.09 | 4.63B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | Truist | Buy |
| May-09-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-07-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-11-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-07-25 | Initiated | Scotiabank | Sector Perform |
| Dec-13-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-03-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Aug-26-24 | Resumed | UBS | Buy |
| May-20-24 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
Can PTC Therapeutics Inc. stock continue upward trendJuly 2025 Trends & Smart Money Movement Alerts - baoquankhu1.vn
Ptc Therapeutics stock hits 52-week high at 61.17 USD - Investing.com
Bayforest Capital Ltd Purchases New Shares in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. $PTCT Shares Acquired by Parkman Healthcare Partners LLC - MarketBeat
Insider Sell: David Southwell Sells 12,000 Shares of PTC Therape - GuruFocus
Eric Pauwels Sells 39,850 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU - Insider Monkey
Adage Capital Partners GP L.L.C. Has $30.32 Million Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
AQR Capital Management LLC Boosts Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
Insider Sell Alert: Eric Pauwels Sells 39,850 Shares of PTC Therapeutics Inc (PTCT) - GuruFocus
How sensitive is PTC Therapeutics Inc. to inflationJuly 2025 Recap & AI Based Buy and Sell Signals - Lancaster City Council
Bank of America Securities Keeps Their Buy Rating on PTC Therapeutics (PTCT) - The Globe and Mail
Canada Pension Plan Investment Board Raises Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Given Overweight Rating at Cantor Fitzgerald - MarketBeat
PTC Therapeutics at Morgan Stanley Conference: Strategic Insights and Updates - Investing.com Canada
PTC Therapeutics To Challenge BioMarin's Metabolic Disorder TreatmentBioMarin Pharmaceutical (NASDAQ:BMRN) - Benzinga
BofA Securities Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $76 - 富途牛牛
Can PTC Therapeutics Inc. Overcome Bearish Sentiment2025 Short Interest & Technical Entry and Exit Tips - beatles.ru
Volume Surge May Signal Institutional Interest in PTC Therapeutics Inc.Trade Ideas & AI Enhanced Trade Execution Alerts - beatles.ru
PTC Therapeutics, Inc.'s (NASDAQ:PTCT) Shares Bounce 26% But Its Business Still Trails The Industry - simplywall.st
PTC Therapeutics (NASDAQ:PTCT) Director Sells $83,600.05 in Stock - MarketBeat
PDT Partners LLC Lowers Stock Holdings in PTC Therapeutics, Inc. $PTCT - MarketBeat
PTC Therapeutics, Inc. $PTCT is Palo Alto Investors LP's 8th Largest Position - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Trading 6.1% HigherStill a Buy? - MarketBeat
PTC Therapeutics, Inc. $PTCT Shares Acquired by Ieq Capital LLC - MarketBeat
Real time scanner hits for PTC Therapeutics Inc. explained2025 Risk Factors & AI Based Buy and Sell Signals - Newser
Heatmap analysis for PTC Therapeutics Inc. and competitorsJuly 2025 Opening Moves & Reliable Price Action Trade Plans - Newser
What institutional flow reveals about PTC Therapeutics Inc.July 2025 Reactions & Short-Term High Return Strategies - Newser
Is PTC Therapeutics Inc. stock a good pick for beginners2025 Sector Review & Weekly Setup with ROI Potential - خودرو بانک
What to expect from PTC Therapeutics Inc. in the next 30 daysJuly 2025 Setups & Entry Point Confirmation Signals - Newser
Is now a turning point for PTC Therapeutics Inc.Earnings Beat & Safe Entry Zone Identification - Newser
Ptc Therapeutics stock hits 52-week high at 58.61 USD By Investing.com - Investing.com Canada
PTC Therapeutics, Inc. $PTCT Position Trimmed by Armistice Capital LLC - MarketBeat
PTC Therapeutics' SWOT analysis: stock poised for growth amid regulatory challenges - MSN
Technical analysis overview for PTC Therapeutics Inc. stockQuarterly Trade Summary & Consistent Profit Trading Strategies - Newser
Applying Wyckoff theory to PTC Therapeutics Inc. stock2025 Winners & Losers & Long-Term Growth Plans - Newser
Real time alert setup for PTC Therapeutics Inc. performanceMarket Trend Summary & Free Weekly Watchlist of Top Performers - Newser
What is PTC Therapeutics Inc.’s valuation compared to sectorJuly 2025 Weekly Recap & Risk Controlled Swing Alerts - خودرو بانک
Institutional scanner results for PTC Therapeutics Inc.Stop Loss & Verified Short-Term Trading Plans - Newser
Ptc Therapeutics stock hits 52-week high at 58.61 USD - Investing.com
Transcript : PTC Therapeutics, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-04-2025 11 - MarketScreener
Here's Why Shares in PTC Therapeutics Soared This Week - Mitrade
PTCT Stock Surges After Promising Outlook for Sephience - GuruFocus
Transcript : PTC Therapeutics, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-03-2025 08 - MarketScreener
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):